adar1 capital management buys $53,691 of NextCure stock
ADAR1 Capital Management, LLC, a 10% owner and director of NextCure, Inc. (NASDAQ:NXTC), recently acquired additional shares of the company’s common stock. The investment firm purchased a total of 10,851 shares across three separate transactions in late October, amounting to a total value of $53,691.
The purchases occurred on October 23, 2026, October 26, 2026, and October 27, 2026. Prices for these acquisitions ranged from $4.8294 to $5.0953 per share. On October 23, ADAR1 Capital Management purchased 5,626 shares. This was followed by the acquisition of 1,672 shares on October 26, and a further 3,553 shares on October 27. The insider buying comes as the stock has declined 38% over the past six months, according to InvestingPro data, though the platform’s Fair Value analysis suggests the stock may be overvalued at current levels near $5.71.
These securities are indirectly owned through private investment funds managed by ADAR1 Capital Management, LLC. Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC, is associated with these holdings.
In other recent news, H.C. Wainwright has reiterated its Buy rating for NextCure, setting a price target of $20.00. Additionally, NextCure has announced a reverse merger with Avere Therapeutics. Upon completion, the combined entity will operate under the name Avere Therapeutics and will trade on Nasdaq under the ticker symbol "AVRX". The merger is expected to be finalized in the second half of 2026, pending stockholder approval and other customary closing conditions. These developments reflect ongoing strategic moves by NextCure and have drawn attention from the investment community.